Aptose Biosciences Inc.
| NASDAQ: APTO | Healthcare / Biotechnology / Canada |
| 2.63 | +0.1300 | +5.20% | Vol 11.59K | 1Y Perf -72.22% |
| Oct 4th, 2023 15:59 DELAYED |
| BID | 2.57 | ASK | 3.03 | ||
| Open | 2.62 | Previous Close | 2.50 | ||
| Pre-Market | - | After-Market | 2.68 | ||
| - - | 0.05 1.90% |
| Target Price | 8.00 | Analyst Rating | Strong Buy 1.17 | |
| Potential % | 204.18 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.39 | Earnings Rating | Strong Sell | |
| Market Cap | 17.15M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.26 | |
| Beta | 1.44 |
Today's Price Range 2.582.74 | 52W Range 2.5011.85 | 5 Year PE Ratio Range -7.40-2.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.71% | ||
| 1 Month | -34.90% | ||
| 3 Months | -43.92% | ||
| 6 Months | -70.78% | ||
| 1 Year | -72.22% | ||
| 3 Years | -97.04% | ||
| 5 Years | -92.75% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -52.36 | |||
ROE last 12 Months | -92.09 | |||
ROA (5Y Avg) | -31.78 | |||
ROA last 12 Months | -80.56 | |||
ROC (5Y Avg) | -100.84 | |||
ROC last 12 Months | -82.89 | |||
Return on invested Capital Q | -19.48 | |||
Return on invested Capital Y | -29.66 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 1.24 | ||||
| - | ||||
| - | ||||
| -2.40 | ||||
| -0.59 | ||||
| 1.21 | ||||
| 0.51 | ||||
| 2.59M | ||||
| Forward PE | -0.39 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.40 | ||||
| 5.50 | ||||
| 0.00 | ||||
| 0.01 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -2.09 | -2.27 | -8.61 |
| Q01 2023 | -1.80 | -2.25 | -25.00 |
| Q04 2022 | -1.65 | -1.65 | 0.00 |
| Q03 2022 | -1.80 | -1.65 | 8.33 |
| Q02 2022 | -1.95 | -1.65 | 15.38 |
| Q01 2022 | -2.25 | -1.80 | 20.00 |
| Q04 2021 | -0.18 | -0.27 | -50.00 |
| Q03 2021 | -0.17 | -0.13 | 23.53 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -2.16 | -24.14 | Negative |
| 12/2023 QR | -2.07 | -18.29 | Negative |
| 12/2023 FY | -8.65 | -27.77 | Negative |
| 12/2024 FY | -7.14 | 7.27 | Positive |
| Next Report Date | 7th Nov 2023 |
| Estimated EPS Next Report | -2.16 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 11.59K |
| Shares Outstanding | 6.52K |
| Shares Float | 5.87M |
| Trades Count | 125 |
| Dollar Volume | 30.48K |
| Avg. Volume | 37.45K |
| Avg. Weekly Volume | 41.33K |
| Avg. Monthly Volume | 32.80K |
| Avg. Quarterly Volume | 38.22K |
Aptose Biosciences Inc. (NASDAQ: APTO) stock closed at 2.63 per share at the end of the most recent trading day (a 5.2% change compared to the prior day closing price) with a volume of 11.59K shares and market capitalization of 17.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 41 people. Aptose Biosciences Inc. CEO is William G. Rice.
The one-year performance of Aptose Biosciences Inc. stock is -72.22%, while year-to-date (YTD) performance is -69.77%. APTO stock has a five-year performance of -92.75%. Its 52-week range is between 2.5 and 11.85, which gives APTO stock a 52-week price range ratio of 1.39%
Aptose Biosciences Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -80.56%, a ROC of -82.89% and a ROE of -92.09%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aptose Biosciences Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.16 for the next earnings report. Aptose Biosciences Inc.’s next earnings report date is 07th Nov 2023.
The consensus rating of Wall Street analysts for Aptose Biosciences Inc. is Strong Buy (1.17), with a target price of $8, which is +204.18% compared to the current price. The earnings rating for Aptose Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptose Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptose Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.10, ATR14 : 0.22, CCI20 : -149.75, Chaikin Money Flow : -0.66, MACD : -0.33, Money Flow Index : 18.51, ROC : -24.01, RSI : 19.66, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 11.61, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptose Biosciences Inc. in the last 12-months were:
Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.
CEO: William G. Rice
Telephone: +1 650 718-5028
Address: 251 Consumers Road,Suite 1105, Toronto M2J 4R3, ON, CA
Number of employees: 41
TipRanks News for APTO
Thu, 21 Sep 2023 11:32 GMT Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO), Harmony Biosciences Holdings (HRMY) and Atara Biotherapeutics (ATRA)
- TipRanks. All rights reserved.Fri, 11 Aug 2023 17:35 GMT Aptose Biosciences (APTO) Receives a Buy from JonesTrading
- TipRanks. All rights reserved.
